Closing the gap? China’s new regulation on biomedical technologies
Abstract
This paper discusses China's State Council Order No. 818, effective May 1, 2026, which establishes a statutory framework for biomedical technologies at the cellular and molecular levels. The framework is uniquely intervention-based rather than product-based, and it addresses regulatory gaps for cell and gene therapies as well as germline interventions.
Fields of Study & Subjects
Biomedical Ethics and Regulation
Biotechnology and Related Fields
CAR-T cell therapy research
Publication details
- Journal / source
- Stem Cell Reports
- Publisher
- Elsevier BV
- Volume
- 21
- Issue
- 7
- Pages
- 102978–102978
- Publication date
- 25 June 2026
- Language
- EN